Younger men had significantly better mean UF, UB, and SF domain scores one-year after RP than older men. Men < 55 years old are more likely than older men to experience a severe decline of sexual bother but trend toward a lower risk of a severe urinary bother. 
PUK14 WORK PRODUCTIVITY IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM THE MATRIX STUDY
Previous research has demonstrated that overactive bladder (OAB) impacts 34 million people in the US and results in $841 million in lost productivity per year. The objective of this study was to determine whether OAB patients receiving the transdermal oxybutynin patch experience productivity improvements. METHODS: Data were obtained from participants in the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin (MATRIX). Patients enrolled in MATRIX received the oxybutynin patch 3.9 mg/day during this six-month, prospective, multicenter, US study. Selfreported work productivity was captured at baseline, three and six-months using the Work Productivity Questionnaire (WPQ), an 8-question subset of the Work Limitations Questionnaire (WLQ). The WPQ includes physical, mental (concentration), time (interruptions and adherence to schedule) and output (ability to handle workload) scales and a mean WPQ Index was computed to estimate overall productivity loss. A productivity loss score was computed to determine the percent reduction of productivity in study participants compared to healthy individuals. RESULTS: MATRIX enrolled 2878 patients (53.5% working age ; 38.9% (n = 1112) employed) at 327 sites. Of the working age population, 92% were female, 81% were Caucasian, and the most common occupations noted were professional (37%), manager/administrator (14.7%) and sales/retail (10.4%). WPQ Index data was available for 740 patients at baseline, 491 at month 3, and 408 at month 6. The mean (SD) WPQ Index score was 8.2 (6.67) at baseline, and decreased significantly at 3-, and 6-months, to 5.8 (5.98), and 5.1 (5.58), respectively (p < 0.0001). Improvements in productivity were observed at 3-and 6-months across time, mental, physical and output domains (p < 0.0001). Overall productivity loss decreased from 7.7% at baseline to 5.5% at month 3 and to 4.8% at month 6. CONCLUSION: Transdermal oxybutynin results in improved work productivity in patients with OAB. This study uses conjoint analysis to examine clinical factors that influence the decision to use specific IgE blood testing as a diagnostic procedure for patients suspected of having allergic rhinitis. METHODS: Participants included a random sample of 50 family physicians in Alabama. For the conjoint analysis physicians evaluated 11 patient profiles (repeated measures) containing four clinical factors: symptom severity, symptom length, patient history, and medication use (prescribed antihistamines, nasal spray, over-the-counter medications). Decisions to test or not test were elicited as dichotomous responses. Visual analog scales were used to support study validity. RESULTS: The largest coefficients were obtained for symptom severity (medium = 2.86; high = 5.12) and symptom length (medium = 1.04; high = 1.03) with history and medication use having moderate influence in the decision process. The overall conditional logistic model was significant (X 2 = 194.8, P < 0.001). All physicians sampled valued testing compared to not testing. For older physicians (age > 50) perceived value compared to not testing was significantly higher (P < 0.05). CONCLU-SIONS: The value of specific IgE testing is strongly linked to how well test results relate to symptoms (severity, length). Family physicians perceive that specific IgE blood testing is valuable to their practice.
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